Immune Checkpoint Inhibitors

Feb 19, 2025

Peptide drug conjugates (PDCs) represent a groundbreaking approach in targeted therapy, offering a powerful strategy for treating diseases, particularly cancer. Peptide drug conjugates are a class of biopharmaceuticals that combine a therapeutic peptide with a cytotoxic or biologically active drug. The peptide serv...

Nov 22, 2024

NK cell therapies have demonstrated significant clinical efficacy, with studies reporting response rates ranging from 40% to 80% in certain hematologic malignancies. As of recent data, several NK cell therapy candidates are in clinical trials, with notable successes including improved overall survival rates and red...

Oct 14, 2022

Immune checkpoint inhibitors are drugs that inhibit immune checkpoints. These drugs allow immune cells to respond more strongly to cancer by blocking them. This blocks the “off” signal, allowing T-cells to kill cancer cells. Checkpoint inhibitors can be used to treat a variety of cancers, including lung cancer (...

Mar 03, 2022

Noninvasix Granted the US FDA Breakthrough Device Designation for Non-Invasive Monitoring Technology for Sepsis On February 23, 2022, Noninvasix, Inc. received the US FDA breakthrough device designation for its LIVOx™ Central Venous Oxygenation Monitor. It is a non-invasive device and provides real-time, ...